Remove Bioinformatics Remove Pharmacokinetics Remove Therapies
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

Prof Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.

RNA 59
article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

We also leverage existing clinical gene expression data from different subsets of molecularly profiled cancer patients, who differ in a certain aspect of disease or response to a particular therapy. Our assays and bioinformatics modelling can help identify certain indications that are appropriate for DCI while ruling others out.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

Each of these three investigational therapies uses a different approach to treat a highly prevalent disease for which new treatment options are very much needed. TNB-585 complements Amgen’s existing prostate cancer portfolio, which includes acapatamab (formerly AMG 160) and AMG 509, both in Phase 1. ” In June 2021, AbbVie Inc.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

In October 2020 , we completed a second clinical study in healthy volunteers to compare the pharmacokinetics of Treprostinil Technosphere to Tyvaso. The phase 3 ADVANCE OUTCOMES study (NCT03626688) seeks to evaluate approximately 700 PAH patients, randomized 1:1 between oral ralinepag and placebo along with background therapy.

FDA 40
article thumbnail

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Disease Modifying Therapies – Risk Management. Presentation Topic: Disease Modifying Therapies – Mechanism of Action. Author: Zhang. Presentation Number: P0343.